9S
9SO.STU Solasia Pharma K.K
- Market cap
- EUR 11.1M
- P/E
- -
- P/B
- 2.94x
- ROE
- -79.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9SO.STU undervalued?
Graham numberThe Graham number of Solasia Pharma K.K cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Solasia Pharma K.K fundamental analysis
No fundamental analysis for Solasia Pharma K.K yet.
Solasia Pharma K.K stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Solasia Pharma K.K
Solasia Pharma K.K., a specialty pharmaceutical company, develops, imports/exports, and markets pharmaceutical products and medical devices, etc. in Japan. It offers SP-01 Sancuso, a transdermal delivery system that delivers the anti-emetic and granisetron into the patient"s bloodstream to patients receiving chemotherapy; and SP-02 Darinaparsin, a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers, as well as SP-03 episil, an oral liquid …
Full company profileSolasia Pharma K.K financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Solasia Pharma K.K annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 501M | 411M | 318M | 1.31B | 454M | 559M | 1.09B | 617M | 316M | 429M | 16.0M |
| Gross Profit | 501M | 411M | 105M | 1.24B | 244M | 373M | 662M | 337M | 185M | 207M | 12.0M |
| Operating Income | -462M | -1.01B | -2.42B | -1.76B | -4.12B | -2.42B | -2.47B | -1.14B | -1.95B | -860M | -1.14B |
| EBITDA | - | -1.01B | -2.27B | -1.29B | -3.62B | -1.92B | -1.94B | -635M | -1.76B | -862M | -1.10B |
| Net Income | -474M | -1.01B | -2.42B | -1.87B | -4.13B | -2.48B | -2.55B | -1.11B | -1.94B | -876M | -1.16B |
| EPS | - | -11 | -23 | -16 | -34 | -19 | -15 | -6.39 | -8.90 | -3.33 | -4.24 |
| Balance Sheet | |||||||||||
| Total Assets | 3.70B | 6.66B | 7.73B | 7.95B | 5.78B | 3.14B | 3.13B | 2.23B | 1.36B | 2.08B | 1.90B |
| Total Liabilities | 272M | 447M | 641M | 1.03B | 2.12B | 557M | 472M | 354M | 321M | 458M | 445M |
| Shareholders' Equity | 3.43B | 6.21B | 7.09B | 6.92B | 3.65B | 2.59B | 2.66B | 1.87B | 1.04B | 1.62B | 1.45B |
| Cash & Short-term Investments | 1.04B | 3.37B | 4.05B | 4.12B | 2.96B | 714M | 803M | 728M | 875M | 1.38B | 1.29B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -464M | -911M | -2.32B | -828M | -2.79B | -2.47B | -2.07B | -359M | -1.03B | - | -650M |
| Capital Expenditure | 558M | 499M | 257M | 732M | 171M | 163M | 403M | 0.00 | 1.00M | 0.00 | 0.00 |
| Free Cash Flow | - | -1.41B | -2.58B | -1.56B | -2.96B | -2.64B | -2.48B | -359M | -1.03B | - | -650M |
| Ratios | |||||||||||
| ROE | -13.8% | -16.2% | -34.2% | -27.0% | -113.0% | -95.8% | -95.7% | -59.3% | -187.5% | -54.1% | -79.7% |
| ROA | -12.8% | -15.1% | -31.3% | -23.5% | -71.5% | -78.8% | -81.3% | -49.9% | -143.1% | -42.2% | -61.0% |
| Net Profit Margin | -94.6% | -245.2% | -761.6% | -142.5% | -909.0% | -443.3% | -233.3% | -180.2% | -614.2% | -204.2% | -7,237.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Solasia Pharma K.K dividends
Solasia Pharma K.K has not paid dividends in the last 9 fiscal years.
Who owns Solasia Pharma K.K
Ownership data of Solasia Pharma K.K is not available yet.
Solasia Pharma K.K company profile
- Company name
- Solasia Pharma K.K
- Ticker
- 9SO.STU
- ISIN
- JP3436500007
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 16
- Fiscal year end
- December
- Address
- Shiodome Building, Tokyo, Japan, 105-0022
- Phone
- 81 3 6721 8332
- Website
- solasia.co.jp
About Solasia Pharma K.K
Solasia Pharma K.K., a specialty pharmaceutical company, develops, imports/exports, and markets pharmaceutical products and medical devices, etc. in Japan. It offers SP-01 Sancuso, a transdermal delivery system that delivers the anti-emetic and granisetron into the patient"s bloodstream to patients receiving chemotherapy; and SP-02 Darinaparsin, a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers, as well as SP-03 episil, an oral liquid for the treatment of pain associated with oral mucositis. The company was founded in 2006 and is based in Tokyo, Japan.
Solasia Pharma K.K management
5- Mr. Yoshihiro AraiPres and Representative Director
- Mr. Toshio MiyashitaChief Financial Officer, Gen. Mang. of Admin. and Director
- Mr. Koji ShinozakiHead of Bus. Devel. Department
- Shigeru SakamakiHead of Product Devel. Division
- Takashi OnoVP